Zinger Key Points
- In Feb. 2023, Australian health authorities rescheduled MDMA and psilocybin to treat certain conditions.
- Psychiatrists now can use psilocybin-assisted therapies with patients outside a research setting.
- Live on Wednesday June 18: 3 Summer "Power Patterns" Are About to Trigger (One With 90% Win Rate). See Them Here.
The new treatments, given to two people under the guidance of Dr. Eli Kotler and Dr. Ted Cassidy, are framed within Australia's Therapeutic Goods Administration (TGA) program authorizing psychiatrists to provide these medicines for specific mental health conditions.
Kotler and Cassidy, early graduates of Mind Medicine Australia (MMA) in psychedelic-assisted therapies, also supplied the psychedelics to the patients who were treated in Melbourne.
The TGA's decision to reschedule MDMA and psilocybin in February 2023 meant the reclassification of MDMA and psilocybin from Schedule 9 (poisons) to Schedule 8 (controlled substances) on a restricted basis.
Starting July 1, 2023, psychiatrists become authorized prescribers for both psychedelic therapies as part of the protocol for patients with treatment-resistant depression (psilocybin) and treatment-resistant posttraumatic stress disorder (MDMA.)
"This is a hopeful step toward a mental health system that heals humans rather than treats psychiatric disorders, and which values integration over managing symptoms," stated Dr. Eli Kotler.
MMA has accepted numerous applications from Australians seeking access to treatments since March 2022. A growing body of evidence on psychedelic-assisted therapies has been helpful to those with treatment-resistant psychiatric conditions. Available treatments are limited to these patients.
Executive director of MMA Tania de Jong was grateful to "the tens of thousands of Australians, Ambassadors, advisory panel, team and board for their extraordinary support in helping us achieve this historic moment."
Although treatment availability is limited, these sessions represent the first step in the Australian healthcare system's incorporation of psychedelic-assisted therapies as a treatment option for people with long-term suffering. Or, as MMA's chair Peter Hunt AM said, "the beginning of a major shift in our mental healthcare system."
Photo: Benzinga edit with photo by New Africa, GillianVann and Arif_Vector on Shutterstock.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!